Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Masatoshi Kudo,Kaoru Tsuchiya,Tatsuya Yamashita,Hironori Koga,Yuki Nakagawa,Masafumi Ikeda

doi:10.1159/000539205

Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Masatoshi Kudo, Kaoru Tsuchiya + Show 4 more

Open Access

https://doi.org/10.1159/000539205

Copy DOI

Journal: Liver Cancer	Publication Date: May 6, 2024
License type: CC BY-NC 4.0

#Adverse Events Of Special Interest #Impact Of Bevacizumab + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

Full Text